Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Use of real world data to improve drug coverage decisions in China | Synapse

June 15, 2023Open Access

Use of real world data to improve drug coverage decisions in China

WWWen WangQueen Mary University of London JTJing TanXuzhou Medical College JWJing WuChinese University of Hong Kong

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Wen Wang and colleagues discuss the rationale and propose a framework for using real world evidence to support coverage decisions in Chinese setting

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Wang et al. (Thu,) studied this question.

synapsesocial.com/papers/6a0d2938d7cdc72b86656711 https://doi.org/https://doi.org/10.1136/bmj-2021-068911

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1How real-world data compensate for scarce evidence in HTA2016 · 11 citations
2Prostate cancer with bone metastasis in Beijing: an observational study of prevalence, hospital visits and treatment costs using data from an administrative claims database2019 · 34 citations
3Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness2018 · 479 citations
4Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China2020 · 49 citations
5Data Resource Profile: Xiamen registry of pregnant women and offspring (REPRESENT): a population-based, long-term follow-up database linking four major healthcare data platforms2020 · 19 citations